Percutaneous thermal ablation of primary lung cancer

Baère, Thierry De; Tselikas, Lambros; Catena, Vittorio; Buy, Xavier; Deschamps, Frédèric; Palussière, Jean

doi:10.1016/j.diii.2016.08.016

Cited by 78 publications

(51 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some medical institutions, the treatment is offered as an outpatient procedure. Patients with pretreatment pulmonary dysfunction may experience temporary exacerbation of respiratory symptoms after ablation and require oxygen therapy lasting one day to three weeks . It is difficult to clearly define the lowest threshold of pulmonary reserve that can tolerate percutaneous pulmonary thermal ablation.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with pretreatment pulmonary dysfunction may experience temporary exacerbation of respiratory symptoms after ablation and require oxygen therapy lasting one day to three weeks. 22 It is difficult to clearly define the lowest threshold of pulmonary reserve that can tolerate percutaneous pulmonary thermal ablation. de Baere et al reported that they successfully performed percutaneous lung RFA in a patient with a forced expiratory volume in one second (FEV1) of <0.8 L/s.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

et al. 2019

View full text Add to dashboard Cite

BackgroundPrevious studies have documented the therapeutic value of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) for early‐stage non‐small cell lung cancer (NSCLC). However, few studies have focused on patients aged 80 years and older. This retrospective study aimed to evaluate the safety and clinical outcomes of CT‐guided percutaneous MWA in patients aged 80 years and older with early‐stage peripheral NSCLC.MethodsA retrospective analysis of 63 patients aged 80 years and older with cT1a‐2bN0M0 peripheral NSCLC who underwent CT‐guided percutaneous MWA was performed between January 2008 and January 2018 at 11 hospitals in Shandong Province, China.ResultsThe median follow‐up time was 21.0 months. The overall median survival time was 50 months. The cancer‐specific median survival time was not reached in five years. The one‐, two‐, three‐, four‐, and five‐year overall survival rates were 97.1%, 92.6%, 63.4%, 54.4%, and 32.6%, respectively. The one‐, two‐, and three‐year cancer‐specific survival (CSS) rates were 97.9%, 97.9%, and 69.4%, respectively. The four‐ and five‐year CSS rates were not achieved. A total of 14 patients (22.2%) had local progression. The one‐, two‐, three‐, four‐, and five‐year local control rates were 88.8%, 78.8%, 70.3%, 63.9%, and 63.9%, respectively. The mortality rate was 0% within 30 days after the procedure. Major complications included pneumothorax requiring drainage (21.1%), pulmonary infection (4.2%), and pleural effusions requiring drainage (2.8%).ConclusionsCT‐guided percutaneous MWA is a safe and effective modality for treating patients aged 80 years and older with early‐stage peripheral NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Current ablation modalities frequently used include MWA, cryoablation, and irreversible electroporation (IRE). 20 RFA and MWA both achieve controlled heating at the tip of the applicator, which leads to tissue coagulation necrosis and tissue death. RFA achieves this through a rapid alternating electric current that is transmitted through the RFA applicator into the lesion and back to the RFA generator through grounding pads or a grounding electrode.…”

Section: Lung Malignancymentioning

confidence: 99%

Microwave Ablation in Primary Lung Malignancies

Moussa

Ziv

Solomon

et al. 2019

Semin intervent Radiol

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality worldwide. Eighty-five percent of cases correspond to non-small cell lung cancer (NSCLC) and pivotal nonsurgical options for early-stage disease include percutaneous ablation and stereotactic body radiation therapy (SBRT). Microwave Ablation (MWA) is a locoregional treatment option that has many advantages over radiofrequency ablation and has been able to overcome the limitations of this technique in the treatment of early-stage NSCLC. In this review article, we highlight the current evidence supporting the use of MWA in patients with early-stage NSCLC and discuss the technical considerations of the procedure, including optimal patient selection and planning strategies, as well as the potential complications and reported outcomes. Finally, we mention future trends involving ablation in NSCLC, including its role in combination with SBRT in central tumors, management of post-SBRT local recurrence, and its potential as an adjuvant treatment option for patients with resistance to systemic therapy or in combination with checkpoint inhibitors.

show abstract

“…Recent studies have shown that following RFA, early‐stage NSCLC patients who cannot tolerate surgical resection (tumor diameter ≤ 3 cm) have one, three, and five‐year survival rates of 90%, 70%, and 50%, respectively, and a mortality rate of < 2% . This clinical evidence leads us to believe that RFA may become a new treatment modality following surgery, radiotherapy, and systemic therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have shown that following RFA, early-stage NSCLC patients who cannot tolerate surgical resection (tumor diameter ≤ 3 cm) have one, three, and fiveyear survival rates of 90%, 70%, and 50%, respectively, and a mortality rate of < 2%. 72 This clinical evidence leads us to believe that RFA may become a new treatment modality following surgery, radiotherapy, and systemic therapy. However, the efficacy of RFA still needs to be validated in prospective, randomized, multi-center clinical trials, 73 and comparison with other treatment, including surgery, [74][75][76][77] ablation 78 and SBRT [79][80][81][82] is necessary.…”

Section: Discussionmentioning

confidence: 99%

Expert consensus on image‐guided radiofrequency ablation of pulmonary tumors: 2018 edition

Liu

Fan

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20–30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80–90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post‐ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.

show abstract

Percutaneous thermal ablation of primary lung cancer

Cited by 78 publications

References 48 publications

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study

Microwave Ablation in Primary Lung Malignancies

Expert consensus on image‐guided radiofrequency ablation of pulmonary tumors: 2018 edition

Contact Info

Product

Resources

About